Era of direct acting anti-viral agents for the treatment of hepatitis C

doi:10.4254/wjh.v10.i10.670

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8055)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

475

WORD

236

HTML

5166

Figures (1-1)

260

Tables (1-7)

269

Sum=6406

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

777

Download

872

Sum=1649

Oct 27, 2018 (publication date) through Feb 3, 2025

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Oct 27, 2018; 10(10): 670-684
Published online Oct 27, 2018. doi: 10.4254/wjh.v10.i10.670

Table 4 Genotype 2-4 infection - treatment-naïve (with compensated cirrhosis) and non-cirrhotic

No.	First line therapy	Alternative regimen
Genotype 2 infection - treatment-naïve and non-cirrhotic
1	Glecaprevir/Pibrentasvir (Mavyret) - 8 wk	Daclatasvir(Daklinza) plus Sofosbuvir (Sovaldi) - 12 wk
2	Sofosbuvir/Velpatasvir (Epclusa) - 12 wk
Genotype 2 infection - treatment-naïve with compensated cirrhosis
1	Glecaprevir/Pibrentasvir (Mavyret) - 12 wk	Daclatasvir(Daklinza) plus Sofosbuvir (Sovaldi) - 16 to 24 wk
2	Sofosbuvir/Velpatasvir (Epclusa) - 12 wk
Genotype 3 infection - treatment-naïve and non- cirrhotic
1	Glecaprevir/Pibrentasvir (Mavyret) - 8 wk	Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) - 12 wk
2	Sofosbuvir/Velpatasvir (Epclusa - 12 wk
Genotype 3 infection - treatment-naïve with compensated cirrhosis
1	Glecaprevir/Pibrentasvir (Mavyret) - 12 wk	Vosevi - Sofosbuvir 400 mg/ Velpatasvir 100 mg/ Voxilaprevir 100 mg when Y93 is present - 12 wk
2	Sofosbuvir/Velpatasvir (Epclusa) - 12 wk	Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) with or without weight-based ribavirin - 24 wk
Genotype 4 infection - treatment-naïve and non-cirrhotic
1	Glecaprevir/Pibrentasvir (Mavyret) - 8 wk	Ombitasvir 25 mg/Paritaprevir 150 mg/ Ritonavir 100 mg (Technivie) with weight-based ribavirin - 12 wk
2	Sofosbuvir/Velpatasvir (Epclusa) - 12 wk
3	Elbasvir/Grazoprevir (Zepatier) - 12 wk
4	Ledipasvir/Sofosbuvir (Harvoni) - 12 wk
Genotype 4 infection - treatment-naïve with compensated cirrhosis
1	Sofosbuvir/Velpatasvir (Epclusa) - 12 wk	Ombitasvir 25 mg/Paritaprevir 150 mg/ Ritonavir 100 mg (Technivie) with weight-based ribavirin - 12 wk
2	Glecaprevir/Pibrentasvir (Mavyret) - 12 wk
3	Elbasvir/Grazoprevir (Zepatier) - 12 wk
4	Ledipasvir/Sofosbuvir (Harvoni) - 12 wk

Citation: Ahmed M. Era of direct acting anti-viral agents for the treatment of hepatitis C. World J Hepatol 2018; 10(10): 670-684
URL: https://www.wjgnet.com/1948-5182/full/v10/i10/670.htm
DOI: https://dx.doi.org/10.4254/wjh.v10.i10.670